Estrogen receptor α, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers

[1]  B. Iacopetta,et al.  DNA hypermethylation in breast cancer and its association with clinicopathological features. , 2006, Cancer letters.

[2]  J. Surrallés,et al.  Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. , 2006, Cancer letters.

[3]  O. Olopade,et al.  BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. , 2005, Cancer research.

[4]  Jacqueline A. Hall,et al.  CpG island methylation of DNA damage response genes in advanced ovarian cancer. , 2005, Cancer research.

[5]  A. Richardson,et al.  BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles , 2005, Breast Cancer Research and Treatment.

[6]  D. Seripa,et al.  Nonrandom Distribution of Aberrant Promoter Methylation of Cancer-Related Genes in Sporadic Breast Tumors , 2004, Clinical Cancer Research.

[7]  H. Stevenson,et al.  Molecular and Cellular Determinants of Estrogen Receptor Expression , 2004 .

[8]  Katia Basso,et al.  Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. , 2004, Cancer research.

[9]  O. Olopade,et al.  Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer , 2004, Clinical Cancer Research.

[10]  V. Jordan,et al.  Selective estrogen receptor modulation: concept and consequences in cancer. , 2004, Cancer cell.

[11]  S. Seal,et al.  Evaluation of Fanconi Anemia genes in familial breast cancer predisposition. , 2003, Cancer research.

[12]  C. Mathew,et al.  Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors , 2003, Nature Medicine.

[13]  A. Richardson,et al.  Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors. , 2003, Cancer research.

[14]  O. Olopade,et al.  FANCF methylation contributes to chemoselectivity in ovarian cancer. , 2003, Cancer Cell.

[15]  W. B. Archey,et al.  Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers , 2002, Oncogene.

[16]  Joanna R. Morris,et al.  BRCA1 methylation: a significant role in tumour development? , 2002, Seminars in cancer biology.

[17]  Michael D Feldman,et al.  Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. , 2002, Cancer research.

[18]  Martin Koš,et al.  0888-8809/01/$03.00/0 Molecular Endocrinology 15(12):2057–2063 Printed in U.S.A. Copyright © 2001 by The Endocrine Society Minireview: Genomic Organization of the Human ER � Gene Promoter Region , 2022 .

[19]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells , 2001 .

[20]  G. Casey,et al.  Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  S. Ganesan,et al.  Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. , 2001, Molecular cell.

[22]  P. Roland,et al.  Loss of estrogen receptor (ER) expression in endometrial tumors is not associated with de novo methylation of the 5' end of the ER gene. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  J. Herman,et al.  Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. , 2000, Cancer research.

[24]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[25]  A. Lindblom,et al.  Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma , 2000, International journal of cancer.

[26]  Daniel Birnbaum,et al.  Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes , 1999, Cancer.

[27]  S. Weitzman,et al.  Mapping of ER gene CpG island methylation-specific polymerase chain reaction. , 1998, Cancer research.

[28]  J. Herman,et al.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Link,et al.  Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. , 1997, Cancer research.

[30]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Herman,et al.  E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. , 1995, Cancer research.

[32]  B. Horsthemke,et al.  Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma , 1994, Human Genetics.

[33]  S. Baylin,et al.  Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. , 1994, Cancer research.

[34]  L. Arrighi,et al.  [Treatment of breast cancer]. , 1971, Prensa medica argentina.

[35]  H. Stevenson,et al.  Molecular and cellular determinants of estrogen receptor alpha expression. , 2004, Molecular and cellular biology.

[36]  A. D’Andrea,et al.  The Fanconi anaemia/BRCA pathway , 2003, Nature Reviews Cancer.

[37]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. , 2001, Cancer research.

[38]  F. Gannon,et al.  Minireview: genomic organization of the human ERalpha gene promoter region. , 2001, Molecular endocrinology.

[39]  S. Weitzman,et al.  Mapping of ER gene CpG island methylation-specific polymerase chain reaction. , 1998, Cancer research.